TG-0054 has been under development by TaiGen since the company's founding in 2001. It is currently enrolled in a phase I trial under the auspices of the US Food and Drug Administration (FDA), and is also undergoing phase II clinical testing in Taiwan.
TG-0054 是太景 2002 年創立以來，自行研發合成、且通過美國食品藥物管理局（FDA）批准進入第一期臨床試驗的我國首例自製新藥，目前正在台灣進行第二期臨床試驗。